Neumentum, Inc. Chief Executive Officer, Scott Shively, To Present at 2019 BIO International Convention in Philadelphia, PA

by admin | May 15, 2019 | In The Media, Press Releases

PALO ALTO, Calif., May 15, 2019 – Neumentum, a pharmaceutical company dedicated to transforming the way pain is treated – without opioids – today announced that Scott Shively, Chief Executive Officer, will present at the 2019 BIO International Convention being held...

Neumentum Phase I Study Confirms Its Non-Opioid in Development for Moderately Severe Acute Pain, NTM-001, Performs in Healthy Adults as Predicted

by Megan Mileusnic | Jan 7, 2019 | In The Media, Press Releases

– The Phase I Clinical Study of a Continuously Infused NSAID, NTM-001, Provided Steady Plasma Levels of Ketorolac Over 24 Hours, With No Unexpected Adverse Effects – Alcohol-Free, Stable Formulation of Ketorolac in a Pre-Mixed Bag for Continuous Infusion Has the...

Neumentum Announces Dosing of Patients in Phase I Study Evaluating Its Lead Product Candidate, NTM-001, a Non-Opioid in Development for the Management of Moderately Severe Acute Pain

by admin | Sep 6, 2018 | Press Releases

– Potential to be the First Continuously Infused NSAID to be Successfully Developed for Acute Post-Operative Pain in the US – NTM-001 is an Investigational, Alcohol-Free, Stable Formulation of Ketorolac in a Pre-Mixed Bag for Continuous Infusion with the...

Neumentum Confirms Type B Meeting with FDA and Announces New Chief Medical and Scientific Officers

by admin | Feb 26, 2018 | Press Releases

— May 8 Type B meeting confirmed to discuss the clinical development program for lead product candidate NTM-001, which has potential to treat moderately severe acute postoperative pain that requires analgesia at the opioid level, reducing the need for opioids in...

Neumentum Raises $6 Million in Series A Funding to Develop Non-opioid Pain Products and Requests Type B Meeting with FDA

by admin | Dec 6, 2017 | Press Releases

— Led by proven executive team, Neumentum is dedicated to becoming a leading non-opioid analgesic and neurology specialty pharmaceutical company — — Type B meeting requested to discuss phase 3 program for lead product candidate NTM-001, which has the...